Consider a long position in NVIDIA (NVDA), which is viewed as a core holding for the AI boom and potentially undervalued. The highest conviction short is InMune Bio (INMB), with a price target of $0.50 due to perceived flaws in its clinical science. Investors may also consider shorting the quantum computing sector, specifically tickers like IONQ, DWAVE, and RGTI, which are seen as overvalued. Vore (VOR) is also identified as a short opportunity because of its high valuation and risky business model as a corporate turnaround. For a bullish biotech play, consider Sarepta (SRPT), but limit portfolio allocation to 5-10% due to its risk profile.

NVIDIA (NVDA)

• The speaker is extremely bullish on NVIDIA, calling it the "best company in the world" and suggesting it is "still really cheap."
• He predicted two years ago that NVIDIA would be the first company to reach a $10 trillion market cap and seems to be sticking with that prediction.
• The recent launch of Grok 4, a new AI model, is cited as a reason to be bullish and buy the stock.
• It is noted that NVIDIA's stock price has a correlation of almost 1 with AMD (AMD), meaning they tend to move in perfect sync.

Takeaways

• The sentiment is overwhelmingly positive, viewing NVDA as a core long-term holding for exposure to the AI boom.
• Investors might see any dips as buying opportunities, based on the speaker's conviction.
• The high correlation with AMD suggests that news affecting one company will likely impact the other, which is a key consideration for portfolio diversification.

Quantum Computing Sector (IONQ, DWAVE, RGTI)

• The speaker is explicitly bearish on the quantum computing sector, stating, "I'm obviously short quantum now."
• His personal portfolio includes short positions in IonQ (IONQ), D-Wave (DWAVE), and Rigetti (RGTI).
• IonQ is highlighted as a significant "underperformer" over the last six months compared to other high-growth tech stocks like Robinhood and Palantir.
• The correlation between IonQ and D-Wave is described as "extremely high," meaning the stocks trade almost identically.
• The speaker notes that these companies, like Ocloo (OCLO), are not yet selling a product, which is a major risk factor.

Takeaways

• This is a strong bearish call on the entire publicly-traded quantum computing space. The speaker believes these stocks are overvalued and likely to fall.
• Investors holding these stocks should be aware of this negative sentiment and the high correlation between them, which limits diversification within the sector.
• The core thesis for the short position appears to be a lack of commercial products and significant underperformance relative to peers in the broader tech market.

Vore (VOR)

• The speaker initially considered shorting VOR, believing it "looks like overvalued."
• He notes that the company's market cap is "much, much, much bigger than it looks" due to a recent financing deal.
• The company is described as a "crapshoot" and a "recap" (recapitalization) of a previously failed company that is being rebuilt with new assets.
• After consulting with a trusted colleague, the speaker confirms his decision: "Vore is a short."

Takeaways

• The speaker has a clear bearish stance on VOR, viewing it as a short-selling opportunity.
• The primary concerns are its valuation, complex financial structure, and risky nature as a corporate turnaround.
• Investors are advised to "stay away from it," as there are "better situations to be involved in."

InMune Bio (INMB)

• The speaker expresses extreme bearishness towards InMune Bio, calling it a "piece of junk."
• INMB is the speaker's biggest short position.
• He has a price target of "$0.50 at some point" for the stock.
• He criticizes one of the company's clinical trials for its poor design, comparing it to a "stupid ass trial" that lacked a proper control (placebo) group.

Takeaways

• This is a high-conviction short idea from the speaker.
• The bearish thesis is based on a belief that the company's science and clinical trial methodology are flawed, which will ultimately lead to failure.
• This is a very high-risk trade, but the speaker is confident the stock will decline significantly.

ATYR Pharma (ATYR)

• The company is described as having a "binary event coming up" related to its drug candidate, F-zofitimod.
• The speaker is conducting a deep dive into the company but expresses initial skepticism about the available data.
• He questions the validity of a "post hoc analysis of a 37 patient trial," suggesting the data is weak and looks like "noise."

Takeaways

• ATYR is presented as a high-risk, high-reward biotech stock facing a critical catalyst.
• The speaker is leaning bearish due to what he perceives as weak clinical data, but he is still in the process of analysis.
• Investors should be aware that the outcome of the upcoming event could cause a massive swing in the stock price in either direction.

Speaker's Portfolio Summary

The speaker explicitly shared the composition of his personal trading account.

• Long Positions (Bullish Bets):

  • Sarepta (SRPT): A biotech long. He advises caution, suggesting a portfolio allocation of only 5-10%.
  • Tarsus (TARS)
  • Biohaven (BHVN)

• Short Positions (Bearish Bets):

  • InMune Bio (INMB): His largest short position.
  • IonQ (IONQ)
  • D-Wave (DWAVE)
  • Rigetti (RGTI)
  • QBT (likely the ticker for a quantum computing company)
  • Joby (JOBY)

Takeaways

• The portfolio is heavily weighted towards shorting the quantum computing sector.
• The long positions are focused on specific biotech companies with catalysts or theses the speaker finds compelling.
• This provides a clear view of the speaker's highest-conviction ideas, both bullish and bearish.

General Market & Tech Stocks

• Apple (AAPL): Discussed in the context of a potential $30 billion acquisition of Perplexity, an AI company. This would be a major strategic shift for Apple, which is seen as being "embarrassed" and under pressure on the AI front.
• Tesla (TSLA): Mentioned as a "general" (a large, heavily traded stock). A recent example was given where the stock dropped on political news from Elon Musk, and a trader (Dave Portnoy) successfully bought the dip, with the stock quickly recovering.
• Google (GOOGL): The speaker is bearish on leadership, stating, "Google needs a new CEO. It's pretty obvious."
• Robinhood (HOOD): Noted as being up on "great earnings." Its stock chart is shown to be nearly identical to HIMSS (HIMS), with a correlation of "virtually one." It has more than doubled in the last six months.
• Palantir (PLTR): Mentioned as a "general" and a "high flyer" that has outperformed quantum stocks like IonQ.
• Regeneron (REGN): The speaker expressed a positive but brief sentiment: "I like Regeneron, yeah."

Takeaways

• Pairs Trading: A major theme was using correlation analysis for pairs trading. The near-perfect correlation between Robinhood (HOOD) and HIMS (HIMS), and NVIDIA (NVDA) and AMD (AMD), are key examples. This is a strategy where you might buy one and short the other if their price ratio deviates from the norm.
• AI Strategy: Large tech companies like Apple and Google are being scrutinized for their AI strategies. A potential acquisition of Perplexity by Apple could be a game-changer for Apple's competitive position.
• Trading Psychology: The Tesla example illustrates a simple "buy the dip" thesis that worked, suggesting that sometimes simple, event-driven trades can be effective.

Broader Investment Themes

• Chinese Economy: The speaker is very bearish on China's economy. He believes the situation is "much worse than it looks," citing high youth unemployment and the government's decision to stop reporting certain economic data.
• Artificial Intelligence (AI): This is the dominant theme. The speaker believes the key challenge for AI companies is not building the technology but selling it. He notes that privately held AI companies are already generating $20 billion in aggregate revenue, indicating massive growth.
• Space Economy: The discussion around Varda Space Industries highlights the "picks and shovels" of the space economy. The business model involves using microgravity to create purer or novel drug formulations that can't be made on Earth. This is a long-term, speculative theme focused on unique manufacturing advantages.

Takeaways

• Investors should be cautious about exposure to the Chinese economy based on the speaker's commentary.
• AI remains the most significant growth theme, but the focus is shifting from pure technology to commercialization and sales execution.
• The space economy presents novel, long-term investment opportunities in areas like in-orbit manufacturing, but these are highly speculative.